Matching BRCA and prostate cancer in a public health system: Report of the Italian Society for Uro-Oncology (SIUrO) consensus project

Crit Rev Oncol Hematol. 2023 Apr:184:103959. doi: 10.1016/j.critrevonc.2023.103959. Epub 2023 Mar 13.


The recent approval of PARP inhibitors for the treatment of metastatic -castration-resistant prostate cancer (mCRPC) patients with BRCA mutations firstly introduced the possibility of proposing a targeted treatment in this disease. However, the availability of this therapeutic option raises a number of questions concerning the management of prostate cancer in everyday clinical practice: the timing and method of detecting BRCA mutations, the therapeutic implications of the detection, and the screening of the members of the family of a prostate cancer patient with a BRCA alteration. These challenging issues led the Italian Society for Uro-Oncology (SIUrO) to organise a Consensus Conference aimed to develop suggestions capable of supporting clinicians managing prostate cancer patients. The present paper described the development of the statements discussed during the consensus, which involved all of the most important Italian scientific societies engaged in the multi-disciplinary and multi-professional management of the disease.

Keywords: Inherited risk; Metastatic castration-resistant prostate cancer; Niraparib; Olaparib; PARP inhibitor; Prostate cancer; Rucaparib.

Publication types

  • Review

MeSH terms

  • Humans
  • Male
  • Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use
  • Prostatic Neoplasms, Castration-Resistant* / pathology
  • Public Health*


  • Poly(ADP-ribose) Polymerase Inhibitors